CONTACTS
|
|
Phone: (706) 721-3410 |
|
Email: jshe@mcg.edu |
|
Room: CA4126 |
|
Address: |
| Medical College of Georgia, |
| CBGM, 1120 15th Street, |
| CA4126, |
| Augusta, GA 30912 |
| MCG Faculty Page |
EDUCATION
|
| Post-doc., Immunogenetics, |
| University of Florida |
| |
| Ph.D., Molecular Genetics, |
| University of Montpellier, France |
| |
| M.S., Fish Biology, |
| National School of Agriculture, France |
| |
| B.S., Fish Biology, |
| Agricultural College of Central China |
|
|
JIN-XIONG SHE:
DIRECTOR CBGM
|
RESEARCH INTEREST
Dr. She's research focuses on the elucidation of genetic and immunological mechanisms of human diseases, particularly type 1 diabetes. The experimental approaches include genetic mapping and positional cloning of disease genes, functional genomics, proteomics, creation and analysis of animal models for human diseases, and high throughput screening of drug-like chemical compound libraries. The ultimate goals of the research programs are to understand the pathogenesis of the diseases and to develop better prediction, prevention and intervention strategies.
|
|
|
Mouse Genetics
Using mouse models of various human conditions, this program seeks to identify genes responsible for various diseases including type 1 diabetes, pancreatitis and lymphoma. Congenic, transgenic and knockout technologies combined with high throughput gene expression arrays and proteomics tools are used to dissect the contribution of various genes to the complex disease phenotypes.
|
Human Genetics
Using various genetic mapping tools and functional studies, this program seeks to understand the genetic basis of human complex diseases including type 1 diabetes and other autoimmune diseases.
|
Functional Genomics
High throughput genomic technologies are used to investigate the normal function of the immune system as well as its malfunction in autoimmune diseases. These tools are also applied to human patient populations to identify biomarkers for various human diseases including type 1 diabetes, diabetic complications and cancer.
|
Proteomics
This program is developing various proteomic tools for the identification and quantification of complex proteomes. Proteomic platforms include Luminex beads, 2D PAGE, 3D proteomics using 2D HPLC and various mass spectrometry techniques (LTQ, MALDI-TOF/TOF and SELDI). These techniques are used to understand the cellular functions of various systems as well as biomarker discovery for human diseases (clinical proteomics).
|
TEDDY: The Environmental Determinants of Diabetes in the Young
This is a clinical center of the international consortium, TEDDY (The environmental determinants of diabetes in the young), which aims at identifying the environmental triggers for type 1 diabetes in genetically susceptible individuals. TEDDY screens over 400,000 newborns in six international centers and identifies 8,000 high risk babies for long term (15 years) follow-up studies.
|
TEDDY RNA Laboratory
The TEDDY RNA Laboratory is a high throughput facility to purify large numbers of RNA and DNA samples collected by the TEDDY study, which aims at identifying the environmental triggers for type 1 diabetes in genetically susceptible children.
|
PANDA: Prediction and Prevention of Type 1 Diabetes
The PANDA (prospective assessment in newborns of diabetes autoimmunity) was established in 1997 and seeks to screen newborns and young relatives of type 1 diabetes patients using genetic markers. The high risk subjects are monitored prospectively and at regular time intervals. Samples collected from these cohort are used to investigate the immunopathogenesis of type 1 diabetes using a variety of approaches including genetics, genomics, proteomics and cellular immunology tools. High risk subjects may also be enrolled for clinical trials aimed at preventing diabetes or its complications.
|
High Throughput Drug Screening
This programs seeks to identify drug candidates through high throughput screening of large libraries of drug-like chemical compounds. Drug candidates are further tested in cells and pre-clinical models.
|
|
|
|
|
|
|
Lack of correlation between the levels of soluble cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) and the CT-60 genotypes.
|
|
Purohit S, Podolsky R, Collins C, Zheng W, Schatz D, Muir A, Hopkins D, Huang YH, She JX
|
|
Center for Biotechnology and Genomic Medicine, Medical College of Georgia, Augusta, GA 30912, USA. spurohit@mail.mcg.edu
|
|
Proteomic analysis of SUMO4 substrates in HEK293 cells under serum starvation-induced stress.
|
|
Guo D, Han J, Adam BL, Colburn NH, Wang MH, Dong Z, Eizirik DL, She JX, Wang CY
|
|
Center for Biotechnology and Genomic Medicine, Medical College of Georgia, 1120 15th Street, CA4098, Augusta, GA 30912, USA.
|
|
Molecular pathways altered by insulin b9-23 immunization.
|
|
Eckenrode SE, Ruan QG, Collins CD, Yang P, McIndoe RA, Muir A, She JX
|
|
CBGM, Medical College of Georgia, 1120 15th Street, CA-4124, Augusta, GA 30912, USA.
|
|
A functional variant of SUMO4, a new I kappa B alpha modifier, is associated with type 1 diabetes.
|
|
Guo D, Li M, Zhang Y, Yang P, Eckenrode S, Hopkins D, Zheng W, Purohit S, Podolsky RH, Muir A, Wang J, Dong Z, Brusko T, Atkinson M, Pozzilli P, Zeidler A, Raffel LJ, Jacob CO, Park Y, Serrano-Rios M, Larrad MT, Zhang Z, Garchon HJ, Bach JF, Rotter JI, She JX, Wang CY
|
|
Center for Biotechnology and Genomic Medicine, Medical College of Georgia, 1120 15th Street, CA4098, Augusta, Georgia 30912, USA.
|
|
A functional variant of SUMO4, a new I kappa B alpha modifier, is associated with type 1 diabetes.
|
|
Guo D, Li M, Zhang Y, Yang P, Eckenrode S, Hopkins D, Zheng W, Purohit S, Podolsky RH, Muir A, Wang J, Dong Z, Brusko T, Atkinson M, Pozzilli P, Zeidler A, Raffel LJ, Jacob CO, Park Y, Serrano-Rios M, Larrad MT, Zhang Z, Garchon HJ, Bach JF, Rotter JI, She JX, Wang CY
|
|
Center for Biotechnology and Genomic Medicine, Medical College of Georgia, 1120 15th Street, CA4098, Augusta, Georgia 30912, USA.
|
|
|
|
|
|
|
|